science
New gene-editing startup raises $230 million via reverse merger with troubled cancer-research firm
Serapha Bio launched June 23, 2026, after raising $230 million and completing a reverse merger. The startup will develop a one-time gene-editing therapy for Alpha-1 Antitrypsin Deficiency.
newyorker.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Serapha Bio launched on June 23, 2026, to develop a one-and-done gene-editing treatment for Alpha-1 Antitrypsin Deficiency, Stat reported. The company raised $230 million in total funding and completed a reverse merger with Boundless Bio. RA Capital and RTW Investments arranged $138 million in Series A funding for Serapha Bio, with an additional $92 million tied to the reverse merger.
The startup also negotiated contracts with a Chinese drug company. Boundless Bio launched in 2019 to study extrachromosomal DNA and its role in cancer growth but encountered trouble with its lead program. Serapha Bio enters a field of firms developing treatments for the liver and lung disorder AATD.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
